Deal includes three miRNA-based tests for CUP, squamous lung cancer, and mesothelioma.
Warnex Medical Laboratories signed an exclusive distribution agreement in Canada for three currently available tests from Rosetta Genomics. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis.
Warnex will distribute miRview™ mets, which identifies the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview™ squamous, which differentiates squamous from nonsquamous, non-small-cell lung cancer, is also included in the agreement. Finally, Warnex will distribute miRview™ meso, which distinguishes mesothelioma from other carcinomas in the lung.
“This agreement joins our existing contracts with Prometheus Laboratories in the U.S. and with Teva Pharmaceutical in Israel and Turkey,” notes Ronen Tamir, chief commercialization officer at Rosetta Genomics.
